万联证券股份有限公司 关于 宁波美诺华药业股份有限公司 2023 年度向特定对象发行股票 之 发行保荐书 保荐机构（主承销商） 二〇二三年八月 美诺华 2023 年度向特定对象发行股票申请文件 发行保荐书 声 明 万联证券股份有限公司（以下简称"万联证券"或"保荐机构"或"保荐人"） 接受宁波美诺华药业股份有限公司（以下简称"美诺华"或"发行人"）的委托， 担任其 2023 年度向特定对象发行股票的保荐机构。 万联证券股份有限公司及其保荐代表人已根据《中华人民共和国公司法》（下 称"《公司法》"）、《中华人民共和国证券法》（下称"《证券法》"）、《上 市公司证券发行注册管理办法》（下称"《注册管理办法》"）和《证券发行上 市保荐业务管理办法》（下称"《保荐管理办法》"）等有关法律、行政法规和 中国证券监督管理委员会（下称"中国证监会"）的有关规定，诚实守信，勤勉 尽责，严格按照依法制订的业务规则、行业执业规范和道德准则出具本发行保荐 书，并保证所出具文件的真实性、准确性和完整性。 本发行保荐书中如无特别说明，相关用语与《宁波美诺华药业股份有限公司 2023 年度向特定对象发行股票募集说明书》中的含义相同。 3 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2023-074 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 序 | | | 产品 | 产品 | 金额 | 已履行的 | | --- | --- | --- | --- | --- | --- | --- | | 号 | 受托方 | 产品名称 | 类型 | 期限 | （万元） | 审议程序 | | 1 | 交通银行 | 交通银行股份有限公司 2023 年第 90 期企业大额 存单 | 大额 存单 | - | 1,000 | 已经公司2023年4月2 日召开的第四届董事 会第十七次会议、第四 | | | | | | | | 届监事会第十六次会 | | | | | | | | 议，以及 2023 年 4 月 | | | | | | | | 24 日召开的 2022 年年 | | | | | | | | 度股东大会审议通过 | | | 合计 | ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥246,318,328.09, representing a decrease of 50.76% compared to the same period last year[4] - The net profit attributable to shareholders was ¥43,448,818.81, down 62.30% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,890,801.07, a decline of 89.08% compared to the previous year[4] - Basic earnings per share were ¥0.21, down 72.37% from the previous year[4] - Diluted earnings per share were ¥0.20, a decrease of 71.43% compared to the same period last year[4] - The weighted average return on net assets was 2.06%, a decrease of 4.31 percentage points year-on-year[4] - Total revenue for Q1 2023 was ¥246,318,328.09, a decrease of 50.8% compared to ¥500,209,863.60 in Q1 2022[18] - Net profit for Q1 2023 was ¥46,218,606.15, a decline of 63.6% from ¥126,813,489.39 in Q1 2022[19] - Operating profit for Q1 2023 was ¥56,064,797.51, down 60.9% from ¥143,525,351.09 in Q1 2022[19] Cash Flow and Liquidity - The net cash flow from operating activities was -¥16,639,241.51, reflecting a decrease of 131.60% year-on-year[4] - In Q1 2023, the cash inflow from operating activities was CNY 279,804,657.39, a decrease of 27.6% compared to CNY 386,525,685.65 in Q1 2022[22] - The net cash flow from operating activities was negative at CNY -16,639,241.51, contrasting with a positive CNY 52,664,102.21 in the same period last year[22] - Cash inflow from investment activities totaled CNY 291,138,530.74, significantly higher than CNY 94,579,344.47 in Q1 2022[22] - The net cash flow from investment activities was CNY -101,092,484.23, slightly improved from CNY -101,364,941.96 in Q1 2022[22] - Cash inflow from financing activities was CNY 138,468,439.40, down from CNY 196,935,200.00 in the previous year[23] - The net cash flow from financing activities was CNY 23,574,767.30, a decrease of 58.6% compared to CNY 56,829,526.44 in Q1 2022[23] - The cash and cash equivalents at the end of Q1 2023 stood at CNY 468,943,485.90, compared to CNY 380,939,246.25 at the end of Q1 2022[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,427,481,086.30, an increase of 0.18% from the end of the previous year[5] - Total assets as of Q1 2023 were ¥4,427,481,086.30, slightly up from ¥4,419,458,473.75 at the end of Q1 2022[16] - Total liabilities decreased to ¥2,198,904,259.95 in Q1 2023 from ¥2,246,218,288.08 in Q1 2022, a reduction of 2.1%[16] - The company's cash and cash equivalents decreased to RMB 677,394,093.81 from RMB 791,943,106.69, representing a decline of about 14.4%[14] - The company's receivables, including accounts receivable, decreased to RMB 151,742,630.92 from RMB 168,844,670.64, a reduction of about 10.1%[14] Shareholder Information - The top shareholder, Ningbo Meinuohua Holding Group Co., Ltd., holds 21.22% of the shares, totaling 45,285,661 shares[11] - The second-largest shareholder, Yao Chengzhi, owns 5.66% of the shares, amounting to 12,070,253 shares[11] - The company reported a total of 9,080,630 shares held through margin trading by major shareholders[12] Operational Insights - The decrease in revenue was primarily due to a reduction in COVID-related orders and the exclusion of Liao Yuan Pharmaceutical from the consolidated financial statements[8] - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[12] - Research and development expenses for Q1 2023 were ¥11,580,047.95, an increase of 35.9% from ¥8,531,863.08 in Q1 2022[19] - The company plans to focus on market expansion and new product development in the upcoming quarters[19] Inventory and Current Assets - As of March 31, 2023, the company's total current assets amounted to RMB 1,924,253,063.05, an increase from RMB 1,894,382,271.16 at the end of 2022, reflecting a growth of approximately 1.9%[14] - The company's inventory increased to RMB 648,072,367.50, up from RMB 594,415,030.12, indicating a rise of approximately 9.0%[14] - The total non-current assets reached RMB 2,113,000,000, with significant investments in fixed assets totaling RMB 1,250,877,425.99[14] - The total amount of trading financial assets increased to RMB 308,899,668.81 from RMB 217,377,643.31, reflecting a growth of approximately 42.2%[14]

关于举办2022年度网上业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议问题征集：投资者可于 2023 年 4 月 26 日至 5 月 5 日 16:00 前登录 上证路演中心网站首页（http://roadshow.sseinfo.com），点击"提问预征集"栏 目进行提问。公司将于 2022 年度业绩说明会上，在信息披露允许范围内对投资 者普遍关心的问题进行回答。 一、说明会类型 | | | 宁波美诺华药业股份有限公司 独立董事：包新民 四、投资者参加方式 （一）投资者可在 2023 年 5 月 8 日 15:00—16:30，通过互联网登录上证路 演中心（http://roadshow.sseinfo.com），在线参与本次业绩说明会，公司将在信 息披露允许范围内对投资者普遍关心的问题进行回答。 （二）投资者可于 2023 年 4 月 26 日至 5 月 5 日 16:00 前登录上证路演中心 网站首页（http://roadshow.sseinfo.com），点击"提问预征集" ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,456,982,442.23, representing a 15.80% increase compared to CNY 1,258,147,710.17 in 2021[24]. - The net profit attributable to shareholders for 2022 was CNY 338,745,242.93, a significant increase of 137.67% from CNY 142,526,366.01 in the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 232,154,300.81, up 84.26% from CNY 125,996,077.55 in 2021[24]. - The net cash flow from operating activities for 2022 was CNY 276,951,746.66, an increase of 25.53% compared to CNY 220,628,551.71 in 2021[24]. - The company's total assets at the end of 2022 were CNY 4,419,458,473.75, a 10.45% increase from CNY 4,001,495,468.56 at the end of 2021[24]. - The weighted average return on equity for 2022 was 17.57%, up from 8.54% in 2021, indicating improved profitability[25]. - The basic earnings per share for 2022 were CNY 1.61, a 136.76% increase from CNY 0.68 in 2021[25]. - The company achieved a compound annual growth rate of 69.79% in net profit attributable to shareholders after deducting non-recurring gains and losses over the past three years[26]. - The company achieved total revenue of approximately CNY 1.46 billion, representing a year-on-year growth of 15.80%[86]. - Net profit attributable to shareholders reached CNY 339 million, a significant increase of 137.67% compared to the previous year[86]. Dividend Distribution - The company reported a cash dividend distribution of 0.165 CNY per share (including tax) for the fiscal year 2022[6]. - The total cash dividends distributed amounted to ¥30,263,320.56[200]. Audit and Compliance - The company has received a standard unqualified audit report from the accounting firm[5]. - The company has not faced any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has not faced any issues with more than half of the directors being unable to guarantee the authenticity of the annual report[8]. - The company's financial report is confirmed to be true, accurate, and complete by its responsible personnel[5]. - The company has detailed potential risks in the report, particularly in the section discussing future development[8]. - The board of directors and supervisory board members have all attended the board meeting, ensuring accountability[4]. Research and Development - The R&D team has grown to 594 personnel, reflecting a year-on-year increase of 25.86%, with a focus on drug synthesis and process development[80]. - The company has established a comprehensive R&D quality system and project management process to ensure scientific integrity and traceability[81]. - The company reported a research and development investment of CNY 119.83 million, representing a year-on-year increase of 20.16%[138]. - The total R&D investment reached 119.83 million yuan, representing 8.22% of operating revenue, with capitalized R&D accounting for 18.09%[104]. - The company is actively pursuing new drug development and has a robust pipeline of products in various stages of research and approval[136]. - The company has multiple ongoing projects in various therapeutic areas, including hypertension, diabetes, and oncology, with several in the small-scale research phase[131]. - The company is focusing on expanding its product offerings in the cardiovascular and diabetes treatment markets[131]. Business Expansion and Strategy - The company is advancing its strategic transformation by integrating intermediates, APIs, and formulations, leveraging its supply chain advantages[43]. - The company is actively developing innovative technologies in areas such as siRNA and synthetic biology, with initial orders already delivered[39]. - The company completed the acquisition of 100% equity in Xuancheng Meinuohua, enhancing its CDMO capabilities[41]. - The company is expanding its production capacity, with the completion of a 3 billion tablet capacity facility expected to enhance its CMO business[48]. - The company is focusing on optimizing its quality management system, having passed 19 domestic official inspections and 46 inspections from well-known domestic and international companies, receiving high praise for its quality management[55]. - The company is committed to sustainable development and aims to become a leading pharmaceutical enterprise in China by deepening its focus on niche markets[158]. - The company is diversifying its business structure to mitigate cyclical impacts, focusing on CDMO and formulation growth alongside stable raw material production[162]. Market Trends and Industry Insights - The global pharmaceutical market is expected to grow at a CAGR of 3%-6% from 2022 to 2026, reaching nearly $1.8 trillion by 2026, driven by increasing drug demand and aging population[57]. - China's pharmaceutical expenditure is projected to grow at a CAGR of 3.8%, reaching $205 billion by 2026, supported by the increase in innovative drug launches and usage[60]. - The global CDMO market for intermediates and APIs was estimated at approximately $83 billion in 2020, with a projected growth to $236.7 billion by 2024, reflecting a compound annual growth rate (CAGR) of 6.12%[65]. - The penetration rate of outsourced R&D services in the pharmaceutical industry increased from 32.6% in 2014 to 37.2% in 2018, and is expected to reach 48.0% by 2023[62]. - China's CDMO market share rose from 5.9% in 2011 to 8.9% in 2017, indicating significant growth potential compared to leading overseas CDMO companies[63]. Corporate Governance - The company has established a sound corporate governance structure and internal control system, ensuring compliance with relevant laws and regulations[169]. - The board of directors operates independently, with no interference from controlling shareholders, ensuring the company's decision-making and operational independence[170]. - The board has four specialized committees that effectively guide and supervise the execution of board resolutions, contributing to scientific decision-making[171]. - The supervisory board has fulfilled its responsibilities in monitoring the legality and compliance of the company's operations and financial status[172]. - The management team strictly adheres to the company's articles of association and board resolutions, with no instances of exceeding authority[173]. - The company ensures timely and accurate information disclosure, adhering to the principles of fairness, justice, and openness[173]. Employee and Talent Management - The total number of employees in the parent company is 125, while the main subsidiaries employ 2,172, resulting in a total of 2,297 employees[195]. - The educational background of employees includes 8 with a doctorate, 78 with a master's degree, 577 with a bachelor's degree, 483 with an associate degree, and 1,151 with a high school education or below[195]. - The company has implemented a stock option and restricted stock incentive plan to attract and retain key talent, aligning interests among shareholders and management[85]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 2.8149 million yuan[184]. Sales and Marketing - The company’s CDMO sales model focuses on contract-based custom development and production, primarily serving domestic and international pharmaceutical companies[142]. - The company emphasizes direct sales and distributor sales for its raw materials and intermediates, with a strong focus on export markets[142]. - The company plans to explore new sales models in large circulation and expand into grassroots and OTC markets[145]. - The company has established a new pharmaceutical sales subsidiary, Ningbo Meinuohua Pharmaceutical Sales Co., Ltd., to expand its sales capabilities[145].

Group 1: Financial Performance - The company's first quarter recorded a significant revenue increase of 47.86% and a non-net profit increase of 142.75% year-on-year [3] - In 2021, the revenue from raw materials and intermediates decreased by 21.5%, with expectations for improvement in 2022 [4] - The company achieved a non-net profit growth of 143% in the first quarter of 2022, with CDMO business growing by 296% and formulation business by 50% [7] Group 2: Business Strategy and Development - The company aims to focus on specialty raw materials, with CDMO and formulation businesses as dual wings for strategic upgrade [5] - The company has established business cooperation with over 100 domestic and international pharmaceutical companies, with ongoing projects exceeding 200 [7] - The company is actively recruiting high-end talent to enhance its core competitiveness, with total personnel exceeding 2,500 [8] Group 3: Market and Operational Challenges - The company faced challenges due to international market price fluctuations, rising raw material costs, and exchange rate movements in 2021 [4] - The Shanghai pandemic impacted the shipping rhythm, but the overall production and operation remained stable [10] - The company reassured investors that the recent fire incident did not result in casualties but was a significant event, and measures are being taken to mitigate negative impacts on customer relations [6] Group 4: Future Outlook - The company expects to maintain double-digit growth in CDMO and formulation businesses, with a strong focus on small nucleic acid business development [5] - The company has completed the layout for new products and anticipates that the new business volume will resonate with the increased production capacity to support stable business development [10] - The company is optimistic about the commercialization of nine projects in collaboration with Merck, which will contribute to new growth points in performance [7]

2022 年第三季度报告 证券代码：603538 证券简称：美诺华 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 | | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 比上年同 | 年初至报告期末 | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 333,378,633.01 | ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[12]. - The company's revenue for the first half of 2022 reached ¥897.31 million, a 29.74% increase compared to ¥691.63 million in the same period last year[20]. - Net profit attributable to shareholders was ¥184.66 million, reflecting a 58.71% increase from ¥116.35 million year-on-year[20]. - The net profit for the first half of 2022 was RMB 205,552,083.68, representing a 62.8% increase compared to RMB 126,178,486.77 in the first half of 2021[164]. - The company aims for a revenue growth target of 25% for the full year 2022[12]. - The company reported a significant growth in its CDMO and formulation business, indicating a strong market demand[22]. - The company achieved total operating revenue of 897 million yuan, a year-on-year increase of 29.74%[31]. - The net profit attributable to shareholders reached 185 million yuan, up 58.71% compared to the same period last year[31]. - The company reported a decrease in comprehensive income attributable to the parent company, totaling RMB 184,216,214.58, compared to RMB 116,498,348.67 in the first half of 2021[165]. Research and Development - The company has allocated 50 million RMB for research and development in new technologies and product lines[12]. - R&D expenses surged by 69.89% to CNY 44.11 million, driven by enhanced process optimization and increased investment in R&D projects[67]. - The company is committed to continuous R&D innovation, with a focus on developing complex organic synthesis reactions and ensuring safety through advanced laboratory facilities[41]. - The company has three R&D centers with over 13,000 square meters of laboratory space, employing 376 raw material researchers and 139 formulation researchers, marking a 13% increase in R&D personnel year-on-year[40]. - The company is focusing on small nucleic acid drugs as a major area for future CDMO business growth, having already established capabilities in this field[50]. Market Expansion and Strategy - The company has successfully entered two new markets in Southeast Asia, increasing its market presence[12]. - The company plans to launch three new products in the second half of 2022, focusing on innovative drug formulations[12]. - The company aims to leverage opportunities in centralized procurement and regional alliances as a long-term growth strategy[30]. - The company is actively pursuing a dual strategy of "internal growth and external expansion" to enhance its integrated business model in the pharmaceutical industry[33]. - The company is exploring potential mergers and acquisitions to expand its market presence in the Asia-Pacific region[183]. Financial Health and Investments - The total assets increased by 9.62% to ¥4.39 billion compared to ¥4.00 billion at the end of the previous year[20]. - The company's net assets attributable to shareholders grew by 9.35% to ¥1.92 billion from ¥1.75 billion at the end of the previous year[20]. - The company reported a total of 364.65 million yuan in trading financial assets at fair value at the end of the reporting period[76]. - The company made a total investment of 151.62 million yuan during the reporting period, a 100.00% increase compared to the previous year, primarily for acquiring minority interests in Xuan Cheng Mei Nuo Hua[73]. - The company has established stable relationships with suppliers to mitigate risks of raw material shortages and price increases[84]. Compliance and Governance - The company has ensured the authenticity and completeness of the semi-annual report, with all board members present at the meeting[6]. - The company maintained a strong compliance record, successfully passing 9 domestic inspections and 21 client audits during the reporting period[63]. - The company has committed to strict adherence to corporate governance and compliance with regulations, ensuring no misuse of control for personal gain[106]. - The company has not reported any violations or penalties against its directors, supervisors, or senior management, indicating a strong compliance culture[108]. - The company has not engaged in any significant related party transactions outside of normal business operations during the reporting period[109]. Environmental Responsibility - The company has implemented effective pollution control measures, including a comprehensive wastewater treatment system and solid waste management practices, ensuring compliance with environmental regulations[96]. - The company reported that its major subsidiary, Zhejiang Meinuohua, is a key pollutant discharge unit, with actual wastewater discharge of 24.10 tons per year for chemical oxygen demand, well below the permitted limit of 112.20 tons per year[95]. - The company has established a comprehensive environmental risk emergency mechanism, ensuring efficient emergency response in case of environmental pollution incidents[98]. - The company has implemented an EHS management system to reduce safety and environmental risks in production[82]. - The wastewater treatment capacity has been steadily improved, and air pollution control has been further strengthened at key production bases[100]. Shareholder Information - The total number of shareholders reached 37,262 by the end of the reporting period[125]. - The company's total share capital increased to 212,982,815 shares after a capital reserve conversion and cash dividend distribution[122]. - The largest shareholder, Ningbo Meinuohua Holding Group Co., Ltd., holds 45,285,661 shares, representing 21.26% of total shares[127]. - The company issued a cash dividend of CNY 0.19851 per share, totaling CNY 30,263,320.56[122]. - The company has a stock option and restricted stock incentive plan that spans from 2021 to 2023, with performance assessments conducted annually[133].

Financial Performance - The company's operating revenue for 2021 was CNY 1,258,147,710.17, representing a year-on-year increase of 5.43% compared to CNY 1,193,373,219.38 in 2020[24]. - The net profit attributable to shareholders for 2021 was CNY 142,526,366.01, a decrease of 8.62% from CNY 155,962,816.48 in 2020[24]. - The net profit after deducting non-recurring gains and losses was CNY 125,996,077.55, which is a significant increase of 56.46% compared to CNY 80,530,167.97 in 2020[24]. - The company's cash flow from operating activities for 2021 was CNY 220,628,551.71, showing a decrease of 3.26% from CNY 228,056,650.17 in 2020[24]. - The total assets at the end of 2021 reached CNY 4,001,495,468.56, an increase of 28.00% from CNY 3,126,187,554.12 at the end of 2020[24]. - The basic earnings per share for 2021 was CNY 0.96, down 9.43% from CNY 1.06 in 2020[25]. - The weighted average return on equity decreased to 8.54% in 2021, down 20.56 percentage points from 10.75% in 2020[25]. Business Growth and Development - The company reported a significant growth in its CDMO and formulation business, contributing CNY 41,792.72 million in revenue, a year-on-year increase of 112.69%[26]. - The company is expected to maintain 100% high-speed growth in CDMO and formulation businesses in 2022, assuming no major changes in the macroeconomic and industry environment[58]. - The company is advancing its "intermediate, API, and formulation integration" strategy to leverage its API advantages and enhance overall competitiveness[51]. - The company is actively expanding its production capacity, with several projects nearing completion, including a 400-ton API project and a 30 billion tablet production project[57]. - The company aims for over 100% revenue growth in both CDMO and formulation businesses for the year, aligning with its strategic transformation goals[59]. Research and Development - The company has a robust R&D team with 365 personnel in raw material drug development and 90 in formulation development, with over 17% holding master's or doctoral degrees[73]. - The total R&D investment reached 99,725,160.83 yuan, representing 7.93% of total revenue, with 11.44% of R&D costs capitalized[96]. - The company has a total of 136 authorized patents, including 66 invention patents and 70 utility model patents[116]. - The company submitted 51 patent applications during the reporting period, with 21 patents granted, including 5 invention patents[116]. - The company is currently in the registration review stage for several key projects, including Moxifloxacin and Sitagliptin raw materials[118]. Corporate Governance - The company is committed to maintaining a robust governance structure, ensuring compliance with relevant laws and regulations, and protecting the interests of investors[153]. - The board of directors operates effectively, with independent directors ensuring compliance and transparency in decision-making processes[154]. - The supervisory board strictly adhered to the company's articles of association and effectively supervised the management's compliance with legal and regulatory requirements[155]. - The management team executed board resolutions without exceeding their authority, ensuring compliance with the company's articles of association[156]. - The company maintained strict information disclosure practices, ensuring timely and accurate reporting in accordance with regulatory requirements[156]. Strategic Partnerships and Market Position - The company has established long-term partnerships with renowned pharmaceutical companies such as Merck, Hengrui, and Innovent Biologics, enhancing its brand recognition and competitive advantage in the CDMO sector[67]. - The company has developed production processes for key intermediates and active pharmaceutical ingredients for COVID-19 treatments, with some products already commercialized[41]. - The company has established business cooperation with over 100 domestic and international pharmaceutical companies in the CDMO sector[38]. - A ten-year strategic cooperation agreement was signed with Merck & Co. in the CDMO field, with multiple projects in different stages of development[42]. Financial Strategies and Capital Management - The company plans to distribute a cash dividend of 0.2 CNY per share, totaling 30,263,346 CNY based on a total share count of 151,316,730 shares as of December 31, 2021[6]. - The company intends to increase capital reserves by issuing 0.4 additional shares for every share held, resulting in a total of 60,526,692 new shares to be distributed[6]. - The company successfully raised RMB 520 million through convertible bonds during the reporting period, significantly boosting financing activities[84]. - The company has proposed to use part of the idle raised funds for cash management, indicating a strategic approach to optimize financial resources[176]. Risk Management - The company has outlined potential risks in its future development discussions, which are detailed in the management analysis section[9]. - The company emphasizes that forward-looking statements do not constitute commitments to investors, highlighting the importance of investment risk awareness[7]. - The company faces product quality control risks due to complex production processes, and will enhance process management and quality awareness to mitigate these risks[147]. - The company is exposed to market competition risks, particularly in the API business, and will actively expand new customer markets and develop new products to enhance competitiveness[148]. Employee and Management Practices - The company has implemented a comprehensive employee training program to enhance skills and professional development[189]. - The company has a competitive compensation policy in place, ensuring compliance with labor laws and providing various insurance benefits to employees[188]. - The total remuneration for all directors, supervisors, and senior management was 3.0467 million yuan[172]. - The company reported a total of 2,473 employees, with 1,234 in production, 75 in sales, 455 in technology, 44 in finance, and 665 in administration[186].

Financial Performance - The company's operating revenue for Q1 2022 was ¥500,209,863.60, representing a year-on-year increase of 47.86%[5] - Net profit attributable to shareholders for the same period was ¥115,262,819.38, reflecting a significant increase of 128.94% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥108,892,837.46, up 142.75% year-on-year[5] - The net cash flow from operating activities reached ¥52,664,102.21, a remarkable increase of 381.04%[5] - The net profit for Q1 2022 was CNY 126,813,489.39, a significant increase of 134% compared to CNY 53,845,524.75 in Q1 2021[21] - The total revenue from operating activities reached CNY 351,455,266.33, up from CNY 236,104,257.15 in the same period last year, representing a growth of approximately 49%[25] - The operating profit for Q1 2022 was CNY 143,525,351.09, compared to CNY 62,682,715.24 in Q1 2021, indicating a year-over-year increase of 128%[21] - The company reported a total comprehensive income of CNY 127,079,016.39 for Q1 2022, compared to CNY 53,748,914.34 in Q1 2021, reflecting an increase of 136%[22] Earnings Per Share - Basic earnings per share for the period were ¥0.76, compared to ¥0.42 in the same period last year[6] - Diluted earnings per share increased to ¥0.70 from ¥0.36 year-on-year[6] - Basic earnings per share for Q1 2022 were CNY 0.76, up from CNY 0.34 in Q1 2021, marking a growth of 124%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,163,321,849.23, up 4.04% from the end of the previous year[6] - Total assets as of March 31, 2022, were RMB 4,163,321,849.23, an increase from RMB 4,001,495,468.56 at the end of 2021[17] - Total liabilities as of March 31, 2022, were RMB 2,010,062,969.44, a slight decrease from RMB 2,022,990,166.99 at the end of 2021[16] - The company's equity attributable to shareholders as of March 31, 2022, was RMB 1,911,704,445.39, up from RMB 1,751,483,976.45 at the end of 2021[17] Cash Flow - Cash and cash equivalents as of March 31, 2022, were RMB 429,284,022.83, slightly up from RMB 421,787,093.24 at the end of 2021[14] - The cash and cash equivalents at the end of Q1 2022 amounted to CNY 380,939,246.25, an increase from CNY 209,931,228.22 at the end of Q1 2021[27] - The cash flow from operating activities generated a net amount of CNY 52,664,102.21, a turnaround from a negative cash flow of CNY -18,738,767.96 in Q1 2021[26] - Investment activities resulted in a net cash outflow of CNY -101,364,941.96 in Q1 2022, compared to CNY -515,062,217.35 in Q1 2021, indicating an improvement in cash flow management[26] Costs and Expenses - Total operating costs for Q1 2022 were RMB 365,195,193.49, up 29.4% from RMB 282,292,447.78 in Q1 2021[20] - Research and development expenses for Q1 2022 amounted to RMB 8,531,863.08, a decrease of 35.5% from RMB 13,210,864.94 in Q1 2021[20] - The company incurred interest expenses of CNY 6,420,495.97 in Q1 2022, a decrease from CNY 6,955,336.01 in Q1 2021, showing a reduction of approximately 8%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 49,077[11] - Inventory as of March 31, 2022, was RMB 577,986,471.00, a slight decrease from RMB 579,688,837.50 at the end of 2021[15] - Short-term borrowings as of March 31, 2022, were RMB 417,661,600.00, down from RMB 425,866,700.00 at the end of 2021[16] Profitability Metrics - The company reported a gross profit margin of 40.49% for the period, driven by strong sales growth in its CDMO and formulation businesses[8] - Gross profit for Q1 2022 was RMB 135,014,670.11, reflecting a gross margin of approximately 27%[20] - The weighted average return on equity rose to 6.37%, an increase of 3.33 percentage points[6]